Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Hydroxybenzaldehyde SCHEMBL28715730 | 0.91 | CTNNB1 (0.51) | CTNNB1HTTNPC1CYP2C9RAB9A | |
| SCHEMBL7971640 | 0.88 | CTNNB1 (0.44) | CTNNB1HTTNPC1CYP2C9RAB9A | |
| SCHEMBL28411450 | 0.88 | CTNNB1 (0.66) | CTNNB1HTTCYP2C9RAB9AKDM4E | |
| SCHEMBL11574074 | 0.85 | CTNNB1 (0.51) | CTNNB1HTTRAB9AKDM4EHPGD | |
| SCHEMBL2562259 | 0.85 | CTNNB1 (0.70) | CTNNB1HTTCYP2C9KDM4EMAPT | |
| SCHEMBL13599494 | 0.85 | CTNNB1 (0.47) | CTNNB1HTTCYP2C9RAB9AKDM4E | |
| SCHEMBL9664968 | 0.84 | CTNNB1 (0.47) | CTNNB1RAB9AKDM4EMAPTKMT2A | |
| SCHEMBL9252102 | 0.84 | CTNNB1 (0.67) | CTNNB1HTTRAB9ANPSR1KDM4E | |
| SCHEMBL1798 | 0.84 | CTNNB1 (0.71) | CTNNB1HTTRAB9ANPSR1KDM4E | |
| SCHEMBL7537752 | 0.83 | TTR (0.50) | NPC1CYP2C9RAB9ANPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553075-B1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO (JP) | 2013-08-14 | — | — | EP | disclosed |
| EP-2565178-A1 | LPA Receptor Antagonists | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-03-06 | — | — | EP | disclosed |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8124645-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-7820682-B2 | LPA receptor antagonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | ONO PHARMACEUTICAL CO., LTD. | 2008-11-27 | — | — | US | disclosed |
| US-20060148830-A1 | Lpa receptor antagonist | ONO PHARMACEUTICAL CO., LTD. | 2006-07-06 | — | — | US | disclosed |
| EP-1553075-A1 | LPA RECEPTOR ANTAGONISTS | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-07-13 | — | — | EP | disclosed |
| EP-0630888-B1 | IMIDAZOLINE DERIVATIVE, PRODUCTION THEREOF, AND BLOOD PRESSURE RETENTIVE | MAEDA HIROSHI (JP) | 2001-04-04 | — | — | EP | disclosed |
| US-5464857-A | Smooth muscle relaxants and removal of nitrogen oxides | HIROSHI MAEDA (JP) | 1995-11-07 | — | — | US | disclosed |
| EP-0630888-A1 | IMIDAZOLINE DERIVATIVE, PRODUCTION THEREOF, AND BLOOD PRESSURE RETENTIVE | Maeda, Hiroshi (JP) | 1994-12-28 | — | — | EP | disclosed |
| US-4900865-A | Method for producing a di-(mono- or poly-)carboxyaryl ether | AMOCO CORPORATION (US) | 1990-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293764-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | CTNNB1 2960/4885HTT 2649/4885NPC1 226/4885 |
| US-20100249157-A2 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | CTNNB1 2960/4885HTT 2649/4885NPC1 226/4885 |
| US-20120088782-A1 | LPA RECEPTOR ANTAGONIST | LPAR1, LPAR2, LPAR4 | CTNNB1 2960/4885HTT 2649/4885NPC1 226/4885 |
| US-20060148830-A1 | Lpa receptor antagonist | LPAR1, LPAR2, LPAR4 | CTNNB1 2960/4885HTT 2649/4885NPC1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.